{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:18:58Z","timestamp":1793391538936,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims:<\/jats:title>\n            <jats:p>Patients diagnosed with single large hepatocellular carcinoma (HCC) often face a daunting prognosis and pose a treatment challenge. In this study, we aimed to evaluate the effectiveness of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) in patients with single large HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>397 patients with resectable single, \u22657 cm HCC from three centers in China between January 2016 and December 2021 were included, 268 patients underwent hepatectomy alone and 129 patients underwent neoadjuvant HAIC. The log-rank test was used to compare the overall survival (OS) and disease-free survival (DFS) by intension-to-treat analysis between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The 1-, 3-, and 5-year OS rates were 83.3%, 62.9%, and 53.8% in the surgery alone group, and 97.5%, 80.7%, and 64.7% in the neoadjuvant HAIC group. The 1-, 3-, and 5-year DFS rates were 48.8%, 32.5%, and 26.2% in the surgery alone group, and 71.5%, 61.7%, and 59.5% in the neoadjuvant HAIC group. The neoadjuvant HAIC group showed significantly longer OS (hazard ratio [HR], 0.506; 95% confidence interval [CI], 0.347\u20130.734; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and DFS (HR, 0.466; 95% CI, 0.357\u20130.609; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) than the surgery alone group. There was no HAIC-related death in the neoadjuvant HAIC group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Neoadjuvant FOLFOX-HAIC significantly improved the OS and DFS with acceptable toxicities in HCC patients with resectable single, \u22657 cm tumor.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000002437","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:01:52Z","timestamp":1747148512000},"page":"3850-3858","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-730X","authenticated-orcid":false,"given":"Zili","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongguo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery, The Affiliated Foshan Hospital of Sun Yat-Sen University, Foshan, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"},{"name":"Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1245\/s10434-010-0976-5","article-title":"Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique","volume":"17","author":"Truty","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s11605-019-04363-1","article-title":"Predicting hepatocellular carcinoma recurrence beyond Milan criteria after liver resection for solitary hepatocellular carcinoma","volume":"24","author":"Kim","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000343875","article-title":"JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan","volume":"3","author":"Kudo","year":"2014","journal-title":"Liver Cancer"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11605-015-2849-5","article-title":"The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients","volume":"19","author":"Hwang","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.23246","article-title":"Resection of large hepatocellular carcinoma (\u226510 cm): a unique western perspective","volume":"107","author":"Shrager","year":"2013","journal-title":"J Surg Oncol"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","article-title":"A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma","volume":"249","author":"Zhou","year":"2009","journal-title":"Ann Surg"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3892\/etm.2015.2822","article-title":"Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent groups in a single center","volume":"10","author":"Zhao","year":"2015","journal-title":"Exp Ther Med"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00270-009-9568-9","article-title":"Analysis of nontarget embolization mechanisms during embolization and chemoembolization procedures","volume":"32","author":"L\u00f3pez-Ben\u00edtez","year":"2009","journal-title":"CardioVasc Interv Radiol"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2018180257","article-title":"A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma","volume":"290","author":"Khalaf","year":"2019","journal-title":"Radiology"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","article-title":"FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2018","journal-title":"Gut"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"102362","DOI":"10.1016\/j.coph.2023.102362","article-title":"Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: applicability in Western countries","volume":"70","author":"He","year":"2023","journal-title":"Curr Opin Pharmacol"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"R21-20250612","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1097\/JS9.0000000000001268","article-title":"The STROCSS 2024 guideline: strengthening the reporting of cohort, cross-sectional, and case-control studies in surgery","volume":"110","author":"Rashid","year":"2024","journal-title":"Int J Surg"},{"key":"R22-20250612","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R23-20250612","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R24-20250612","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R25-20250612","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.surg.2019.11.005","article-title":"Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: a multicenter propensity score matching analysis","volume":"169","author":"Xing","year":"2021","journal-title":"Surgery"},{"key":"R26-20250612","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.surg.2014.09.018","article-title":"Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus","volume":"157","author":"Hu","year":"2015","journal-title":"Surgery"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:02:11Z","timestamp":1749758531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002437","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"2025-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}